Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.


Autoria(s): Ryser, MD; McGoff, K; Herzog, DP; Sivakoff, DJ; Myers, ER
Data(s)

01/06/2015

Formato

32 - 47

Identificador

http://www.ncbi.nlm.nih.gov/pubmed/25979280

S1755-4365(15)00005-5

Epidemics, 2015, 11 pp. 32 - 47

http://hdl.handle.net/10161/9500

1878-0067

Relação

Epidemics

10.1016/j.epidem.2015.01.003

Palavras-Chave #Human papillomavirus vaccination #Male HPV vaccination #Marginal distribution costs #Optimal vaccine distribution #Stochastic agent-based models #Adolescent #Cohort Studies #Cost-Benefit Analysis #Female #Health Care Rationing #Human papillomavirus 16 #Humans #Immunization Programs #Male #Papillomavirus Infections #Papillomavirus Vaccines
Tipo

Journal Article

Cobertura

Netherlands

Resumo

The effectiveness of vaccinating males against the human papillomavirus (HPV) remains a controversial subject. Many existing studies conclude that increasing female coverage is more effective than diverting resources into male vaccination. Recently, several empirical studies on HPV immunization have been published, providing evidence of the fact that marginal vaccination costs increase with coverage. In this study, we use a stochastic agent-based modeling framework to revisit the male vaccination debate in light of these new findings. Within this framework, we assess the impact of coverage-dependent marginal costs of vaccine distribution on optimal immunization strategies against HPV. Focusing on the two scenarios of ongoing and new vaccination programs, we analyze different resource allocation policies and their effects on overall disease burden. Our results suggest that if the costs associated with vaccinating males are relatively close to those associated with vaccinating females, then coverage-dependent, increasing marginal costs may favor vaccination strategies that entail immunization of both genders. In particular, this study emphasizes the necessity for further empirical research on the nature of coverage-dependent vaccination costs.

Idioma(s)

ENG